According to a report from Corse-Matin on September 27, the last cigarette factory in France, Macotab, will close its doors in December. The tobacco facility is located in Furiani, in the Upper Corsica region.
According to reports, the factory produces approximately 850 million cigarettes per year. This decision comes as a result of a project to restructure certain operations in Europe, as the legally sold volume of cigarettes in France continues to decline, being replaced by smuggled and counterfeit goods. Additionally, Philip Morris International (PMI) terminated part of its production contract with Macotab, leading to the ultimate decision to shut down the company. Similarly, due to the same reasons, the Coretab packaging plant project in Reunion Island is also under consideration for closure.
Macotab cigarette factory is the last remaining cigarette manufacturing plant in France since the closure of the Riom factory in 2016. It operates within a production area of 10,000 square meters with only 29 employees. Currently, a major portion of cigarette production in Europe is concentrated in Germany and Poland.
The Macotab factory, established in 1961, is a subsidiary of Seita (Tobacco and Match Industry Development Company) Group, which is a privatized French tobacco monopoly. Since 1995, it has become a subsidiary of Imperial Brands Group and produces cigarettes for Corsica and other regions of France.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
